Tagged with M

Global The issue of COVID-19 vaccine access in developing nations has thrust intellectual property (IP) into global headlines. Against the backdrop of heated arguments both for and against an IP waiver for COVID-related products, the global pharma industry has launched a new initiative on IP, asserting its crucial importance to continued…

Singapore Cerecin’s Charles Stacey outlines the company’s progress in expanding its lead asset into migraine and infantile spasms, how its funding strategy has evolved, why Singapore is still a logical base, and how broader developments in the CNS landscape stand to benefit all stakeholders.   Moving to Singapore was a good…

Pharma Legal Handbook Key facts about biosimilars and biologics in Mexico. Prepared in association with Olivares, a leading global law firm, this is an extract from The Pharma Legal Handbook: Mexico, available to purchase here for GBP 99. 1. Are biosimilar medicines considered the same as generic medicines in your country? No, biosimilars…

Pharma Legal Handbook Key facts about Localization in Mexico. Prepared in association with Olivares, a leading global law firm, this is an extract from The Pharma Legal Handbook: Mexico, available to purchase here for GBP 99. 1. Are there any rules or regulations requiring and/or encouraging localization in your country? What is the…

USA The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the day after that, another two percent. However, the Massachusetts-based company’s CEO Stephane Bancel remains unconcerned and believes that their successful vaccine is just the beginning of the mRNA era…

Pharma Legal Handbook Important legal info for orphan drugs and rare diseases in Mexican pharma. Prepared in association with Olivares, a leading global law firm, this is an extract from The Pharma Legal Handbook: Mexico, available to purchase here for GBP 99.   1. What is the definition of Rare Diseases in your…

Switzerland Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has made the move into cannabis API production.   2020 was defined by an increase in demand for dietary supplements because…

Switzerland Santen is a leading multinational company that specializes in ophthalmology. President and Head for Europe, Middle East and Africa (EMEA) Luis Iglesias highlights the company’s recent transformation through partnerships across a vast array of areas including digital technology and cell and gene. He also discusses how Santen has leveraged its…

Switzerland Swiss-headquartered ADIENNE has made recent headlines after being announced as the first European company to manufacture Russia’s Sputnik V COVID-19 vaccine. President and Founder Antonio Francesco Di Naro explains how the company’s deal with the Russian Direct Investment Fund happened and some of the challenges related to the manufacturing process.…

Singapore Clarence Ngui describes how global orthopaedic product giant Zimmer Biomet has pivoted in APAC in response to the COVID-19 pandemic; how medical education needs differ across the vast APAC region; and the challenges that have kept him at Zimmer for over 24 years.   Asia Pacific as a region represents…

Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…

Asia-Pacific The Top 10 pharma markets in the vast Asia-Pacific region, ranked by market size in USD millions for 2018. China is way out in front with a market size of US 85,778 million, followed by Japan with USD 77,458 million and India at 16,843 million. Made with Visme Infographic Maker